Key Points
- CEO Helen Torley sold 20,000 Halozyme shares at an average price of $104.18, generating $2.08 million. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, leaving her with 767,780 shares.
- Halozyme reported strong quarterly results, with EPS of $2.28 versus the $1.79 consensus and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
- The stock opened at $107.62 near its 52-week high, while analysts maintained an overall “Moderate Buy” consensus. However, the average analyst price target of $91.20 is below the current share price.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total value of $153,397.71.
- On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00.
- On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00.
Halozyme Therapeutics Price Performance
Shares of NASDAQ:HALO opened at $107.62 on Thursday. The firm has a market cap of $12.21 billion, a price-to-earnings ratio of 32.13, a P/E/G ratio of 0.42 and a beta of 0.85. The firm has a fifty day moving average price of $81.71 and a 200 day moving average price of $73.26. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $107.96. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Halozyme Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC increased its position in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 343 shares during the period. MidFirst Bank purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $28,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $30,000. Institutional investors own 97.79% of the company's stock.
Analyst Upgrades and Downgrades
HALO has been the topic of several recent research reports. Weiss Ratings lowered Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, August 14th. Citizens Jmp raised their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research note on Friday, August 7th. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a report on Friday, August 7th. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $91.20.
View Our Latest Stock Analysis on HALO
Halozyme Therapeutics Company Profile
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
